Letrozol Genericon

Letrozole, the active ingredient in Letrozol Genericon, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed to treat hormone receptor‑positive breast cancer in postmenopausal women, reducing estrogen‑driven tumor growth. The product is approved for prescription use across European markets and is distributed to hospitals, pharmacies, and specialized cancer treatment centers.

GNH USA supplies Letrozol Genericon as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. All batches are manufactured under EU GMP standards and undergo rigorous quality testing before release.

Letrozole acts on estrogen‑dependent breast cancer pathways, providing therapeutic benefit in several clinical settings.

Hormone receptor‑positive breast cancer (postmenopausal): reduces tumor progression by lowering systemic estrogen levels. Adjuvant therapy for early‑stage breast cancer (postmenopausal): decreases risk of disease recurrence after surgery. Metastatic breast cancer (postmenopausal): helps control disease spread and prolongs progression‑free survival.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching in muscles, joints, or back. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain. - Sweating: increased perspiration, especially at night.

Serious or Rare Side Effects: - Severe liver injury: jaundice, dark urine, elevated liver enzymes. - Bone fractures (osteoporosis): increased risk of fractures, especially hip and spine. - Pulmonary embolism: sudden shortness of breath, chest pain, rapid heart rate. - Allergic reactions (anaphylaxis): rash, swelling, difficulty breathing. - Elevated cholesterol levels: may require monitoring. - QT interval prolongation: potential cardiac rhythm disturbances.

When prescribing Letrozol Genericon, clinicians should consider several safety measures.

Pregnancy: contraindicated (Category X); avoid use in pregnant women. Breastfeeding: not recommended; letrozole is excreted in milk. Bone health: monitor bone mineral density; consider calcium/vitamin D supplementation. Liver function: assess hepatic enzymes before initiating therapy. Drug interactions: review concomitant medications for potential CYP interactions. Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Letrozole can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Estrogen‑containing hormone therapy: antagonizes letrozole’s effect, reducing efficacy. - Tamoxifen: competitive estrogen receptor modulation may diminish therapeutic benefit. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly lower plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: letrozole may enhance anticoagulant effect; monitor INR. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may increase plasma levels; observe for toxicity. - Cholesterol‑lowering agents (statins): potential for altered metabolism; check lipid profile.